AbbVie, FutureGen joins forces to pioneer next-gen IBD treatment FG-M701
In a significant development in the pharmaceutical industry, AbbVie Inc. (NYSE: ABBV) and FutureGen Biopharmaceutical (Beijing) Co., Ltd. have entered into a licensing agreement to progress FG-M701, an advanced TL1A antibody aimed at revolutionizing the treatment of inflammatory bowel disease (IBD). The collaboration, valued at approximately $1.71 billion including milestones and royalties, marks a pivotal […]